Zolgensma data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonged event-free survival, increased motor function and milestone ach
?|?Source:?Novartis International AG
- Nearly two-thirds of patients (65.6%) in STR1VE-EU have already achieved developmental motor milestones not observed in the natural history of SMA Type 1 at a mean duration of follow-up of 10.6 months, including patients with a more severe phenotype compared to previous studies
- Two-thirds of patients (66.7%) were free of feeding support, an important indicator of stabilization/halting of disease progression
- New interim Phase 3 STR1VE-EU data presented at WMS support the robust clinical evidence that have demonstrated a consistent, transformative benefit across?Zolgensma?clinical trials for the treatment of patients with SMA
- More than 600 patients now treated?with?Zolgensma, including some more than five years post-treatment and more than five years old
# # #
Novartis Media Relations E-mail:?media.relations@novartis.com
Anja von Treskow Novartis External Communications +41 79 392 8697 (mobile) anja.von_treskow@novartis.com Eric Althoff Novartis US External Communications +1 646 438 4335 eric.althoff@novartis.com | Farah Bulsara Speer SVP, Corporate Communications, Novartis Gene Therapies +1 312 543 2881 (mobile) farah.speer@novartis.com |